SkinBiotix technology successful in stability test

RNS Number : 4866Z

SkinBioTherapeutics PLC

03 September 2018

 

SkinBioTherapeutics plc

SkinBiotix^® technology successful in stability testing

Manchester, UK - 3 September 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, is pleased to provide an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.

Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:

"Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month."

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Sandy Jamieson / Richard Nash	Tel: [phone]
Turner Pope Investments (Joint Broker) Ben Turner / James Pope Northland Capital Partners (Joint Broker) Tom Price	Tel: [phone] Tel: [phone]
Instinctif Partners (Media Relations) Melanie Toyne-Sewell / Deborah Bell	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 

END

 

 

UPDEAPPFDAPPEFF